Results 171 to 180 of about 46,564 (215)

Case Report: Olaparib combined with temozolomide and atezolizumab in a case of <i>BRCA2</i>-mutated small-cell transformation of lung adenocarcinoma. [PDF]

Front Oncol
Liu M, Gao P, Liu F, Li D, Wang Y, Yu J.
europepmc   +1 more source

Hereditary ovarian cancer. [PDF]

Discov Oncol
Jurgiel WA, Panasiuk B, Posmyk R.
europepmc   +1 more source

Clinicopathological Characteristics of Lesions Diagnosed by MRI-Guided Biopsy in <i>BRCA1/2</i> Mutation Carriers. [PDF]

Eur J Breast Health
Nagata A, Tozaki M, Taruno K, Nakamura S, Hayashi N.   +4 more
europepmc   +1 more source

Prevalence and spectrum of homologous recombination repair mutations in patients with metastatic prostate cancer from India. [PDF]

Oncologist
Baskarane H, Jain R, Divakar MK, Seth A, Nayak B, Bakhshi S, Sahoo RK, Kumar A, Sharma A, Kaushal S, Haresh KP, Hooda V, Vasudeva P, Singh PP, Agarwal R, Vasundhara S, Agarwal N, Batra A.   +17 more
europepmc   +1 more source

Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a Novel Phenyl Furan-Quinoline-Carboxylic Acid Series. [PDF]

ACS Med Chem Lett
Ferrandi G, Bagnolini G, Poppi L, Masi M, Previtali V, Andonaia A, Varignani G, Veronesi M, De Franco F, Falchi F, Di Stefano G, Girotto S, Roberti M, Cavalli A.   +13 more
europepmc   +1 more source

Re-evaluating hereditary breast and ovarian cancer risk: clinical impact of updated multigene panel sequencing and genetic counseling. [PDF]

Fam Cancer
Gislinge JIP, Byrjalsen A, Naver KV, Clausen HV, Ravn P, Petersen KR, Wadt KAW.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Beyond BRCA1 and BRCA2

Current Problems in Cancer, 2014
A hereditary breast cancer syndrome can present in a variety of ways ranging from an index case of early-onset breast cancer to an incidental finding during an endoscopy or a dermatological examination. A comprehensive review of the patient’s personal and family history is essential to accurately assess the risk for a hereditary cancer syndrome ...
Kimberly, King-Spohn, Robert, Pilarski
openaire   +2 more sources

BRCA2 and Pancreatic Cancer

International Journal of Gastrointestinal Cancer, 2002
Many factors, including a family history of cancer, have been implicated in the development of pancreatic cancer. Among these factors, germline BRCA2 mutations have been clearly associated with the development of this disease, while mutations in BRCA1 appear to have a limited role. Patients with pancreatic cancer and germline BRCA2 mutations tend to be
Ali, Naderi, Fergus J, Couch
openaire   +2 more sources

Tetraploidy in BRCA2 breast tumours

European Journal of Cancer, 2012
Tetraploidy and aneuploidy can be caused by cell division errors and are frequently observed in many human carcinomas. We have recently reported delayed cytokinesis in primary human fibroblasts from BRCA2 mutation carriers, implying a function for the BRCA2 tumour suppressor in completion of cell division.
Asta Bjork, Jonsdottir, Olafur Andri, Stefansson, Johannes, Bjornsson, Jon G, Jonasson, Helga M, Ogmundsdottir, Jorunn E, Eyfjord   +5 more
openaire   +2 more sources

Brca2 hereditary breast cancer pathophenotype

Breast Cancer Research and Treatment, 1997
Four BRCA2 hereditary breast cancer (HBC) families manifested significant excesses of ‘tubular-lobular group’ (TLG) invasive carcinomas and lobular carcinoma in situ/atypical lobular hyperplasia in comparison to BRCA1-HBC cases.
J N, Marcus, P, Watson, D L, Page, S A, Narod, P, Tonin, G M, Lenoir, O, Serova, H T, Lynch   +7 more
openaire   +2 more sources